• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

FDA provides funding for Simulations Plus and University of Florida project for validation of PBPK models for inhaled drugs

According to modeling software company Simulations Plus, the FDA has awarded the company a contract for a project that is intended to improve models of pulmonary absorption of inhaled drugs, with a goal of creating “the foundation of a viable alternative to in vivo studies for the establishment of bioequivalence (BE) for OIDPs.”

The company said that Rodrigo Cristofoletti’s lab at the University of Florida will generate in vitro data that Simulations Plus will use, along with pathophysiology data, to validate the Pulmonary Compartmental Absorption and Transit model in the company’s GastroPlus platform for various inhaled drugs.

Cristofoletti said, “We are very excited about the funding of this FDA contract that allows us to collaborate with Dr. Guenther Hochhaus, Dr. Jürgen Bulitta, and Simulations Plus. Our goal is to allow realization of new models that will bridge the gap between in vitro and human data and guide the development of biopredictive methods to improve the mechanistic understanding of drug performance locally within the lung.”

Simulations Plus Associate Research Fellow James Mullin commented, “Our novel physiologically based biopharmaceutics (PBBM)/PBPK modeling approach within GastroPlus for pulmonary delivery was initiated in 2009 through an industry-funded collaboration, and to date there have been over 25 peer-reviewed journal publications validating the platform across a wide range of drugs and chemicals. This partnership with Dr. Cristofoletti, his team, and the FDA will expand and improve upon our current cutting-edge technology. Ultimately, the strategies that we are outlining and implementing for applying in vitro systems and in silico models hold potential to lower regulatory burden and minimize the need for animal and human studies.”

Read the Simulations Plus press release.

Share

published on November 3, 2022

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews